Exclusive: Cannabis Co. Zelira To Begin Clinical Trials For Chronic Pain In Retired Athletes

Global cannabis research company Zelira Therapeutics ZLD ZLDAF is set to being a cannabinoid-based clinical trial on chronic pain in retired professional and amateur athletes, Benzinga has learned exclusively.

The trial, which could be the first of its kind, was commissioned through a license and management agreement between Zelira and Australian operator Levin Health. Zelira will design and undertake a clinical trial on the efficacy of its proprietary ZTL-106 formulation. Successful results will allow Levin to globally market a clinically-validated formulation targeting chronic pain. 

This is the second clinical trial that Philadelphia-based Zelira has undertaken for its cannabis formulations. In 2020, the company conducted successful Phase 1/2a clinical trials for Zenivol, a cannabis-based insomnia medicine that is now approved for use and available in Australia, where cannabis for medicinal use is federally legal. 

“We are thrilled with this new partnership with Levin Health,” says Zelira CEO Dr. Oludare Odumosu. “This agreement will combine Zelira’s world-class proprietary cannabinoid formulations and drug development with Levin Health’s network and mission to treat sports-related chronic pain with non-opioid, non-steroid treatment options.” 

The clinical trial for ZTL-106 will be undertaken at La Trobe University’s Sport and Exercise Medicine Research Centre in Victoria, Australia.

Odumosu notes that 80% of chronic pain patients are treated for non-cancer related pain and that this type of pain is especially common in current and retired athletes as well as the growing amateur fitness-minded population. 

“The success of this trial can unlock new cannabinoid-based, pharmacological treatment options for sports-related pain, which has the potential to completely change the way we treat chronic pain,” Odumosu concludes.

Encuentra nuestro contenido en Español en El Planteo:

ZLDAF Logo
ZLDAFZelira Therapeutics Ltd
$0.2998-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
-
Growth
-
Quality
-
Value
-
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!

Comments
Loading...